COMMUNIQUÉS West-GlobeNewswire

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
16/03/2026
Companies Resolve Lawsuit in Delaware BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people [...]
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
16/03/2026
- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs of graft rejection [...]
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
16/03/2026
Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro , in vivo and non-human primate study results, that support development candidates in Acumen’s [...]
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
16/03/2026
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated [...]
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
16/03/2026
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
16/03/2026
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea [...]
Cronos Group Inc. to Speak at the 38th Annual ROTH Conference
16/03/2026
TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President [...]
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
16/03/2026
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE [...]
Minutes from Extraordinary General Meeting
16/03/2026
An extraordinary general meeting of PCI Biotech Holding ASA (“the Company”) took place today, 16 March 2026. All the matters on the agenda were approved in accordance with the proposals set out in the meeting notice, [...]
Doctomatic Appoints Tech Veteran Bill Josko as Head of Americas to Scale AI-Driven Remote Patient Monitoring
16/03/2026
BARCELONA, Spain, March 16, 2026 (GLOBE NEWSWIRE) -- Doctomatic, an AI-native platform for remote patient management, announces the appointment of Bill Josko as Head of Americas. Josko, a seasoned executive with more [...]
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
16/03/2026
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and [...]
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
16/03/2026
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/03/2026
WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
16/03/2026
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
16/03/2026
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 [...]
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
16/03/2026
Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investors SANTA CRUZ, Calif., March 16, 2026 [...]
Quipt Home Medical Completes the Previously Announced Arrangement With Affiliates of Kingswood and Forager
16/03/2026
CINCINNATI, March 16, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ” or “ Quipt ”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is [...]
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
16/03/2026
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 [...]
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
16/03/2026
FDA confirmed givastomig’s potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response rate (ORR) as [...]

Pages